Global Bullous Pemphigoid Treatment Market Report and Forecast 2024-2032

Global Bullous Pemphigoid Treatment Market Outlook

The global bullous pemphigoid treatment market is being driven by the rising skin disease treatment market, which attained a value of USD 20.76 billion in 2023. The skin disease treatment market is expected to grow at a CAGR of 3.2% in the forecast period of 2024-2032 to reach a value of USD 27.46 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Rising Accessibility of Healthcare Facilities to Aid the Market Growth of Bullous Pemphigoid Treatment

Region-wise, Europe is a significant region for bullous pemphigoid treatment, contributing to a significant market share. This could be attributed to the high incidence rate of the disease, i.e., 6/7 cases per 1 million persons per year, and accessibility of healthcare facilities within every section of the region. Europe is followed by North America as a large proportion of healthcare providers and treatment centres reside in the region. The market is further aided by the improved technology and reimbursement scenarios that enhance the growth in these regions. Within the Asia Pacific and the Middle East, the countries are expected to witness an exponential growth over the forecast period owing to government efforts in enhancing healthcare facilities and raising awareness in the region owing to the disease and the availability of treatment options.

Bullous Pemphigoid Treatment: Market Segmentation

Bullous pemphigoid treatment involves the treatment of bullous pemphigoid, which is a chronic, inflammatory skin disease that entails the formation of blisters. The bullous varies from generalised, vegetative, urticarial, nodular, vesicular, acral, or infant forms. The incidences of this disease have been more in younger adults and rare in infants. The treatment of bullous pemphigoid involves pain relief medication, ultra-potent, moderate steroids, antibiotics and antiseptics for bacterial infections, and immunosuppressant medication.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

On the basis of mode of administration, the market is divided into:

• Topical 
• Injectable
• Oral

Based on treatment type, the industry can be segmented into:

• Pain Relief Medication 
• Steroids
• Antibiotics and Antiseptics
• Others

By end use, the industry is categorised into:

• Hospitals
• Special Clinics
• Others

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increasing Geriatric Population Globally to Aid the Market Growth of Bullous Pemphigoid Treatment

The market for bullous pemphigoid treatment is being driven by the increasing geriatric population globally, which has led to the heightened rate of occurrence of the disease, and, therefore, the increase in treatment options. The market is further boosted by the common as well as non-expensive medication used in the treatment of the disease. In addition, numerous awareness programmes organised by healthcare organisations and NGOs encourage the proliferation of the market. However, the unavailability of healthcare facilities in several less developed regions across the globe having a rising incidence of the disease limits the market growth of bullous pemphigoid treatment.

Key Industry Players in the Global Bullous pemphigoid treatment Market

The report gives a detailed analysis of the following key players in the global bullous pemphigoid treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report